Effects of MP in PD (human model)
| S.No. | First citation | Year of publication | Country | Targeted disease | Design of the study | Number of participants and age group | Duration of follow-up | Dose | Adverse event | Major finding |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cilia et al. [19] | 2018 | Bolivia | PD | Randomized order and crossover design | 14< 21 years | 16 weeks | 18.7 mg/kg/day | Gastrointestinal side-effects | Clinical response to MP was similar to LD/CD |
| 2 | Cilia et al. [20] | 2017 | Bolivia | PD | Double-blind, randomized, controlled, and crossover | 18, (13 male, 5 female)< 21 years | 16 weeks |
| Fewer dyskinesias | MP-Hd induced greater motor improvement |
| 3 | Contin et al. [21] | 2015 | Italy | PD | Not specified | 1 | One day | 100 mg LD from Mucuna capsules in 2 different sessions | Impaired LD bioavailability from MP | No significant subacute LD motor response was observed |
| 4 | Katzenschlager et al. [22] | 2004 | UK | PD | Randomized, controlled, and double blind crossover trial | 9 (5 women and 4 men) | 4 hours | 15 g/day (500 mg of LD) and 30 g/day (1,000 mg of LD) | Gastrointestinal side-effects, mild and short lasting nausea | Natural sources of LD might possess advantages over conventional LD preparations in the long term management of PD |
| 5 | HP-200 in Parkinson’s Disease Study Group [23] | 1995 | Not specified (multicenter clinical trial) | PD | Open study | 60 (46 male and 14 female)< 59 ± 9 years | 12-week treatment | 7.5 g/day | Mild gastrointestinal in nature | Found to be an effective treatment for patients with PD |
CD: carbidopa; DDCI: dopa-decarboxylase inhibitor; Hd: high dose; LD: leva-dopa; Ld: low dose; MP: Mucuna pruriens; PD: Parkinson’s disease